Featured Publications
Low Programmed Death-Ligand 1–Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma
Zhao J, Yap D, Chan Y, Tan B, Teo C, Syn N, Smyth E, Soon Y, Sundar R. Low Programmed Death-Ligand 1–Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma. Journal Of Clinical Oncology 2021, 40: 392-402. PMID: 34860570, DOI: 10.1200/jco.21.01862.Peer-Reviewed Original ResearchConceptsProgrammed death-ligand 1Combined positive scoreImmune checkpoint inhibitorsKEYNOTE-062First-line treatmentCheckMate-649Checkpoint inhibitorsEsophageal adenocarcinomaKaplan-MeierEstimate time-to-event outcomesFirst-line immune checkpoint inhibitorsPD-L1 combined positive scoreProgrammed death ligand 1 subgroupsPatients treated with pembrolizumabPD-L1-expressing tumorsRandomized phase III trialEfficacy of ICIsPD-L1 subgroupsProgression-free survivalDeath-ligand 1Phase III trialsUS Food and Drug AdministrationPrimary manuscriptsFood and Drug AdministrationCPS-1
2023
Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroups
Wong N, Yap D, Ong R, Zhao J, Chan Y, Tey J, Sundar R, Lim J, Dawood S. Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroups. Annals Of Oncology 2023 PMID: 37871699, DOI: 10.1016/j.annonc.2023.10.122.Peer-Reviewed Original ResearchTreatment of physician's choiceIndividual patient dataOral SERDsMetastatic breast cancerPFS benefitKaplan MeierBreast cancerEstimate time-to-event outcomesHER2- metastatic breast cancerESR1 mutation statusIndividual patient data meta-analysisOverall populationAdvanced breast cancerMeta-analysisMutant subgroupESR1 mutationsEndocrine therapyMutation statusRandomised controlled trialsOverall cohortPooled analysisDrug classesPFSPhysician's choicePreferred Reporting ItemsEfficacy of oral selective estrogen receptor degraders (SERD)s in the treatment of estrogen receptor positive (ER+), HER2-negative metastatic breast cancer (MBC): A stratified analysis of the ESR1 wild type (wt) and mutant (mt) subgroups.
Zhao J, Wong Zhun Hong N, Yap D, Ong R, Sundar R, Lim J, Dawood S. Efficacy of oral selective estrogen receptor degraders (SERD)s in the treatment of estrogen receptor positive (ER+), HER2-negative metastatic breast cancer (MBC): A stratified analysis of the ESR1 wild type (wt) and mutant (mt) subgroups. Journal Of Clinical Oncology 2023, 41: 1096-1096. DOI: 10.1200/jco.2023.41.16_suppl.1096.Peer-Reviewed Original ResearchProgression free survival benefitTreatment of physician's choiceProgression free survivalMetastatic breast cancerEndocrine therapyESR1 mutationsOverall cohortEstrogen receptorKaplan MeierEstimate time-to-event outcomesHER2-negative metastatic breast cancerOral selective estrogen receptor degraderHER2- metastatic breast cancerSurvival dataTreatment of estrogen receptorSelective estrogen receptor degraderOverall populationCompare survival outcomesIPD meta-analysisMeta-analysisEstrogen receptor degraderOral SERDsPFS differenceCompared to ETFree survival